peripheral T-cell lymphoma
Conditions
Interventions
case series:None
Sponsors
The First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. According to the European and American lymphoma classification criteria revised by WHO in 2016, the patient was newly diagnosed with CD30+ PTCL. The eligible histological types included ALK-positive sALCL, ALK-negative sALCL, PTCL-NOS, AITL, EATL and HSTCL. 2. Age =18 3. Have not received anti-lymphoma therapy; 4. Patients treated with Brentuximab Vedotin combined with CHP were selected by clinicians 5. PET-CT or CT/MRI shows at least one two-dimensional measurable lesion (maximum diameter > 1.5cm) 6. women of childbearing age must be confirmed by pregnancy test not pregnant, and willing to take effective measures during the test period and =12 months after the last dose of contraception; Pregnant and lactating women cannot participate; All male subjects used contraception during the study period and =3 months after the last dose 7. can provide informed consent, can understand and comply with the study requirements.
Exclusion criteria
Exclusion criteria: With severe mental illness;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete response rate;Progression-free survival;overall survival; | — |
Countries
China
Contacts
Public ContactHongyan Tong
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed